Amgen Says Phase 3 Data Support Uplizna's Efficacy in Generalized Myasthenia Gravis

MT Newswires Live
03-13

Amgen (AMGN) said Thursday said that a phase 3 trial of its Uplizna drug showed "durable and sustained efficacy" in patients with acetylcholine receptor autoantibody-positive generalized myasthenia gravis with just two doses a year following an initial loading dose.

The company said the study showed that 72.3% of AChR+ patients treated with Uplizna achieved an improvement of at least 3 points in the Myasthenia Gravis Activities of Daily Living score, compared with 45.2% in placebo.

Amgen previously said the trial, which also evaluated muscle-specific kinase autoantibody-positive patients, met its primary endpoint of statistically significant change from baseline in MG-ADL score at week 26 for both the MuSK+ and AChR+ patients taking Uplizna.

The company said it expects to complete filing its application for Uplizna in gMG in H1. The US Food and Drug Administration granted Orphan Drug Designation for Uplizna in gMG.

The drug is currently approved for the treatment of adults with anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder and is under priority review by the FDA for Immunoglobulin G4-related disease with a target action date of April 3.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10